Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory bowel diseases (IBDs) of unknown etiology, characterized by repeated relapse and remission. The efficacy of thiopurine in IBD was first reported in the late 1960s. Thiopurines are used to alleviate the symptoms of IBD, especially UC. These drugs have a steroid-sparing potential and are widely used for the purpose of maintaining long-term remission in steroid-dependent cases. Therefore, thiopurines tend to be used long-term, but adverse events that accompany long-term use, such as lymphoproliferative disorders, must be monitored with care. In contrast, thiopurine plays a critical role in controlling the immunogenicity of biologics. Furthermore, although thiopurine is an old drug, new findings, including the prediction of serious adverse events such as severe alopecia and acute advanced leukopenia, by nudix hydrolase 15 gene polymorphism analysis, as well as the possibility of appropriate drug monitoring by detailed analysis of 6-thioguanine nucleotides have been clarified. However, the consequences of thiopurine withdrawal have not been determined and further studies, including randomized controlled trials, are necessary to answer the clinical question regarding the scenarios in which thiopurine withdrawal is possible.

Keywords: inflammatory bowel disease, ulcerative colitis, crohn's disease, thiopurine, pharmacological action, biological agents

INTRODUCTION

Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory bowel diseases (IBDs) with unknown etiology, characterized by repeated relapse and remission (Ghouri et al., 2020). Rapid induction and ensured maintenance of remission are the foundations of IBD treatment. In UC, remission maintenance therapy is most commonly based on 5-aminosalicylic acid (5-ASA) monotherapy. Contrarily, in cases where it is difficult to maintain remission with 5-ASA monotherapy, immunomodulators (IMs) are used to attain long-term steroid-free remission after initial induction of remission with steroids (Takahashi et al., 2016; Timmer et al., 2016; Matsuoka et al., 2018). IMs are also important for the treatment of CD, where they are used to maintain long-term steroid-free remission and prevent postoperative recurrence (Takahashi et al., 2016; Timmer et al., 2016; Kakuta et al., 2018a; Matsuoka et al., 2018; Gjuladin-Hellon et al., 2019).

The effectiveness of IMs in treating IBD was first reported in the late 1960s (Brooke et al., 1969). Since then, the efficacies of IMs such as azathioprine (AZA), 6-mercaptopurine (6-MP),...
methotrexate, and mycophenolate mofetil have been reported (Smith and Cooper, 2014; Wang et al., 2015). The use of AZA and 6-MP for UC and CD is recommended by the Japanese clinical guidelines (Matsuoka et al., 2018). Herein, we describe the pharmacological actions of thiopurines and their interactions with other drugs. Moreover, we discuss the positioning of thiopurines in the treatment of IBD, as well as the benefits and risks of thiopurine treatment.

**Pharmacological Action and Interaction of Thiopurines**

The metabolic pathways of thiopurines are illustrated in Figure 1. AZA is a prodrug that after absorption into the body via the gastrointestinal tract, is promptly converted nonenzymatically to 6-MP which is subsequently metabolically regulated by xanthine oxidase (XO), thiopurine S-methyltransferase (TPMT), and hypoxanthine guanosine phosphoribosyl transferase (HGPRT) (Derijks et al., 2006). Various studies have reported that the combination of XO inhibitors, allopurinol and thiopurines, increased blood concentrations of 6-thioguanine nucleotides (6-TGN) following its conversion from 6-thioinosine monophosphate (6-TIMP), thereby reducing the dose of thiopurines and enhancing the immunosuppressive effects (Sparrow et al., 2005; Sparrow et al., 2007; Pavlidis et al., 2016). Moreover, 6-MP is converted to 6-methylmercaptopurine (6-MMP) by TPMT; 6-MMP is reportedly associated with an increased risk of liver injury in red blood cells (RBCs) at levels ≥5700 pmol/8×10⁸ RBC (Wang and Weinshilboum, 2006; Colleoni et al., 2013). The TPMT gene exhibits a multitude of genetic polymorphisms that affect its enzymatic activity. In particular, more than 30 TPMT gene variants that affect its activity have been reported (Wang and Weinshilboum, 2006; Colleoni et al., 2013). Numerous studies have been performed to address the clinical issues arising from leukopenia in patients with low TPMT activity, as the condition develops due to elevated levels of 6-TGN (Roblin et al., 2011).

Polymorphisms in TPMT predominantly result from variant alleles that arise from single nucleotide polymorphisms. Compared with the wild-type TPMT, the TPMT variants are significantly unstable and have lower activity. Based on the assessment of the genotype and TPMT activity, guidelines have been formulated in the US and Europe for determining the initial doses of thiopurines (Relling et al., 2019). However, the activity of TPMT varies with ethnicity. While the standard doses of AZA and 6-MP in the US and Europe are 1.5–2.5 mg/kg and 1.0–1.5 mg/kg, respectively, the doses in Japan are 1.0 mg/kg and 0.6 mg/kg, respectively. This is due to the fact that a study confirmed that Asian patients commonly have low TPMT activity (Gomollón et al., 2017; Matsuoka et al., 2018). However, another study reported that the levels of 6-TGN in
blood are maintained at a therapeutic level in the majority of Japanese IBD patients (Komiyama et al., 2008).

As an active metabolite of thiopurines, 6-TGN ultimately exhibits its pharmacological effects in the form of 6-thio-(deoxy)guanosine-triphosphate (6-T(d)GTP). Incorporation of 6-T(d)GTP, which is structurally similar to guanine (a nucleic acid-composing base), into DNA or RNA during chromosome replication or gene transcription leads to the exhibition of its primary role in blocking nucleic acid synthesis and activating lymphocyte proliferation. Previously, blood concentrations of 6-TGN were thought to correlate with the effectiveness of IBD treatment, with numerous studies reporting on the utility of monitoring 6-TGN concentrations (Cuffari et al., 1996; Dubinsky et al., 2000; Osterman et al., 2006; Komiyama et al., 2008). Dubinsky reported that a high concentration of ≥450 pmol/8 × 10^8 RBC is linked to a high risk of bone marrow suppression (Dubinsky, 2004). A meta-analysis by Osterman showed that ≥230–260 pmol/8 × 10^8 RBCs correlated substantially with clinical remission (Osterman et al., 2006). Contrarily, 6-TGN concentrations and effectiveness did not correlate strongly, with large variations potentially causing issues, and suggested that non-6-TGN metabolites/intermediates with immunomodulatory effects may be involved (Lowry et al., 2001; Goldenberg et al., 2004).

**NUDT15 Polymorphism**

Questions relating to the 6-TGN concentration and pharmacological effects of thiopurines were later clarified in studies evaluating nudix hydrolase 15 (NUDT15) gene polymorphisms. After thiopurine treatment, Asian patients occasionally present with acute advanced leukopenia combined with advanced alopecia as an adverse event (AE), which is rarely reported in Western populations (Gearry et al., 2004; Palmieri et al., 2007). For this reason, genetic background has been thought to influence Asian-specific thiopurine-related side effects. With recent advances in genome analysis technology, conducting genome-wide correlation analysis has become feasible with relative ease. In 2014, Yang et al. reported that in Korean patients with CD, advanced leukopenia showed an extremely strong correlation with NUDT15 polymorphism (Yang et al., 2014). Several studies on Asian populations soon followed in the fields of blood disorders, neurological disorders, skin disease, and IBD (Asada et al., 2016; Moriyama et al., 2016; Tanaka et al., 2015; Lee et al., 2016; Liang et al., 2016; Zhu et al., 2016; Kim et al., 2017; Shah et al., 2017; Soler et al., 2018; Kishibe et al., 2018. However, all cases were related to NUDT15 codon 139 gene polymorphism, and almost all patients with homozygous risk (Cys/Cys type) presented with severe leukopenia and complete alopecia. An IBD study on Japanese patients revealed that complete alopecia was not only associated with severe leukopenia but was also strongly associated with a NUDT15 polymorphism (Kakuta et al., 2016). NUDT15 polymorphisms occur at a very low frequency in Europeans and Africans (Moriyama et al., 2016). The allele frequency of another NUDT15 variant, p.Gly17_Val18del, is approximately 2% in Europeans; this variant is also reported to correlate with thiopurine-induced leukopenia (Walker et al., 2019). Nevertheless, none of these reports fully describe the association between complete alopecia and NUDT15 polymorphisms. Given that alopecia is an extremely rare AE in Caucasians patients taking thiopurines, complete alopecia may be considered a problem specific to Asian populations. In particular, complete alopecia may pose a major problem for young patients, as it can manifest not only as scalp hair loss, but also as entire body hair loss, including eyebrows and arm pit hair.

Recently, Kakuta et al. reported a large-scale observational study (MENDEL study) on AEs following the treatment of IBD with thiopurines in Japanese patients (Kakuta et al., 2018b). This Japanese multicenter study analyzed 1,291 Japanese patients with IBD with a history of taking thiopurines and showed that NUDT15 codon 139 gene polymorphism correlated with severe leukopenia and alopecia. This observation led to the inclusion of NUDT15 codon 139 polymorphism detection assays under Japanese national health insurance coverage for thiopurine-naive patients. Thiopurines are not only used to treat IBD but also many autoimmune diseases, and during immunosuppressive therapy after organ transplantation, the ability to predict whether thiopurines will induce early leukopenia and severe alopecia is welcome news for patients. When treating patients with IBD, it is also recommended that thiopurines are avoided in known carriers of the homozygous risk allele (Cys/Cys) at the NUDT15 codon 139 gene. In heterozygous risk allele (Arg/Cys) carriers, thiopurines are started at approximately half the normal dose, whereas in patients with the wild-type allele (Arg/Arg) thiopurines are started at the normal dose (Kakuta et al., 2020).

Patients with NUDT15 polymorphism may exhibit leukopenia as a dose-dependent AE. Therefore, the concentration of thiopurine metabolite 6-TGN was initially predicted to be elevated. However, Asada et al. reported that 6-TGN levels did not fluctuate in patients with NUDT15 polymorphisms (Asada et al., 2016). A study of pediatric cases of acute lymphoblastic leukemia showed that NUDT15 is an enzyme that dephosphorylates the final active metabolite of thiopurines, 6-T(d)GTP, to 6-thio-(deoxy) guanosine-monophosphate (6-T(d)GMP). Moreover, the report showed that coding polymorphisms in NUDT15 suppressed this dephosphorylating function and prevented 6-TGTG and 6-TdGTP from being converted to 6-TGMP and 6-TdGMP. This led thiopurine to exhibit excessive pharmacological effects that were manifested principally as lymphocyte apoptosis via Rac1 inhibition and inhibition of RNA transcription and DNA replication, ultimately causing severe leukopenia (Moriyama et al., 2016). Measurement of 6-TGN concentration includes both 6-T(d)GMP and 6-T(d)GTP; levels of 6-TGN, which had previously been used as an index, do not change with NUDT15 polymorphism. 6-TGTP is incorporated into RNA, and 6-T(d)GTP is incorporated into DNA, where it inhibits RNA transcription and DNA replication, respectively, thereby causing cell apoptosis. 6-TGTP also causes T-lymphocyte apoptosis by inhibiting the activation of GTPase Rac1 (Tiede et al., 2003; Marinković et al., 2014). Therefore, it is suggested that measurement of 6-T(d)GTP concentration is appropriate for efficient drug blood monitoring.
Effects of Thiopurines in Maintaining Remission

Prospective data showing the effectiveness of thiopurine monotherapy in inducing remission in UC remains limited. Ardizzone et al. conducted a single-center blinded control study of 5-ASA at 3.2 g/day group or AZA at 2 mg/kg/day group, given the intention of inducing remission in steroid-dependent patients with UC. They observed that the remission maintenance rate was 19.4% in the 5-ASA group and 52.6% in the AZA group, demonstrating that AZA had a substantially greater remission rate as well as positive effects in reducing steroids (Ardizzone et al., 2006). However, a considerable amount of time is required for thiopurines to exert their effects (Present et al., 1980), and in actual clinical practice, this agent is infrequently used to induce remission and is more often used in conjunction with steroid reduction in steroid-dependent cases or to maintain remission.

Accumulating evidence from randomized controlled trials (RCTs) and meta-analyses have shown the effects of thiopurines in maintaining remission (Hawthorne et al., 1992; Hibi et al., 2003; Gisbert et al., 2009; Timmer et al., 2016). A comparison between AZA and placebo in the Cochrane Database Systematic Review indicated an odds ratio for remission maintenance failure of 0.41 (95% confidence interval, 0.24–0.70) (Timmer et al., 2016). A meta-analysis by Gisbert et al. showed that remission maintenance was achieved in 60% of patients with UC taking thiopurines, but in only 37% taking the placebo or 5-ASA, demonstrating the benefits of thiopurines (Gisbert et al., 2009).

The efficacy of thiopurines in maintaining remission in patients with CD has also long been demonstrated. Candy et al. investigated AZA in conjunction with steroid therapy in patients with CD and reported a markedly higher proportion of patients in remission in the AZA group than in the placebo group after 15 months (Candy et al., 1995).

Recently, powerful immunosuppressive therapies have been introduced to maintain remission, such as anti-tumor necrosis factor-alpha (anti-TNF-α) antibodies and Janus kinase (JAK) inhibitors. These therapies are used in moderate to severe cases with high disease activity as they can induce and subsequently maintain remission. However, in steroid-dependent cases, many guidelines and position statements recommend that an attempt be made to maintain remission using thiopurines prior to these biological agents and JAK inhibitors due to concerns over infection risks and malignancy since many of these expensive drugs are administered via injection (Harbord et al., 2017; Matsuoka et al., 2018; Lamb et al., 2019).

Relationship of Thiopurines With Biological Agents and Small-Molecule Drugs

By virtue of the introduction of biological agents, clinical treatment for IBD has made considerable progress. At the current height of biological agents, thiopurines are attracting attention for their pharmacological effects for the loss of response (LOR) (Gisbert and Panés, 2009; Bartels et al., 2011; van Schouwenburg et al., 2013).

Infliximab (IFX) was the first biological agent introduced to treat IBD; however, as it showed characteristics of a chimeric biological agent due to the approximately 25% mouse genes, whether this agent should be started as monotherapy or in combination with thiopurines remains contentious. In the SONIC study, the effects of thiopurine monotherapy, IFX monotherapy, and combination therapy of IFX and thiopurines were compared in patients with CD who had not received biological agents or thiopurines (Colombel et al., 2010). This study demonstrated that the clinical remission rate at 26 weeks was substantially greater in the combination therapy group than in the monotherapy group. The appearance ratio of anti-biological antibodies was low in the combination therapy group, and decreased blood concentration of biological agents were confirmed to markedly affect treatment outcomes. The “SUCCESS” RCT, that was similar to the SONIC study, was conducted on 239 patients with moderate to severe UC, who did not receive biologics or thiopurine drugs. The main outcome of that study was the steroid-free remission rate at 16 weeks after starting treatment in the IFX monotherapy, thiopurine monotherapy, and combination therapy groups. The remission rates were 24%, 22%, and 40%, respectively, demonstrating that the steroid-free remission rate was markedly greater in the combination therapy group (Panaccione et al., 2014). These results, similar to the aforementioned SONIC study, indicated not only the substantial involvement of thiopurines suppressing the immunogenicity of IFX, but also some effects of thiopurine itself. A meta-analysis that included four articles indicated that the SUCCESS trial, post-hoc analysis of ACT1 and 2, suggested that regardless of previous use of thiopurines, the combination therapy showed a substantially greater remission rate at 4–6 months, although the remission rate at 12 months was not starkly different between combination therapy and monotherapy (Lichtenstein et al., 2009; Christophorou et al., 2015). Presently, the principal biological agents used for treating IBD are human-type biologics and biosimilars. The DIAMOND study is a Japanese RCT which examined the efficacy of thiopurines in combination with a human-type biologic (Matsumoto et al., 2016). This study investigated the efficacy of adalimumab (ADA), a human-type anti-TNF-α antibody preparation, in combination with thiopurine, for patients with moderate to severe CD who were naïve to both biologics and thiopurines. However, the DIAMOND study did not elucidate the differences between combination therapy and monotherapy. Although no statistically significant differences were observed in the ADA trough levels and anti-ADA antibody levels, the combination group which was administered ADA and thiopurine, exhibited higher ADA trough levels, and contained a lower proportion of patients positive for anti-ADA antibodies compared to the monotherapy group.

Furthermore, as a different concept from SONIC, SUCCESS, and DIAMOND study, some study has been made of whether the
additional administration of thiopurine restores therapeutic responsiveness when LOR occurs with anti-TNF-α antibody monotherapy. Macaluso et al. reported an analysis of 46 IBD patients treated with anti-TNF-α antibody and additionally treated with thiopurines, methotrexate, and mycophenolate mofetil (Macaluso et al., 2018). Results of this study show that additional combination therapy was effective in 42.4% of CD and 53.8% of UC. Moreover, the average dose of AZA used at that time was a low dose. These results indicate that the addition of low-dose IM is an effective and safe optimization strategy when LOR occurs with anti-TNF-α antibody monotherapy.

Small-molecule drugs are believed to not elicit anti-drug antibodies, and hence do not induce a LOR via anti-drug antibodies. The JAK inhibitor, tofacitinib, is a small-molecule drug. A report indicated that a stronger therapeutic effect was achieved following the administration of thiopurines in combination with tofacitinib. However, the design of the large-scale OCTAVE trial did not allow tofacitinib to be used in combination with tofacitinib. Therefore, the safety of two-agent therapy has yet to be verified. Additionally, the use of thiopurines in combination with tofacitinib has not been recommended due to the risk of infection, particularly viral infection, associated with tofacitinib itself, and concerns that two-agent therapy may induce excessive immunosuppression that could break down the intestinal barrier, thereby making it difficult to control disease activity (Sandborn et al., 2017; Xiong et al., 2019; Feng et al., 2020). Clear evidence is currently lacking on the clinical significance of long-term combination use of biological agents and thiopurines.

Thiopurine-Associated AEs Are Not Linked to NUDT15 Polymorphisms

Various AEs are often observed with thiopurine treatment. The frequency of AEs in patients with IBD varies from 9% to 35%, depending on the study (Fraser et al., 2002; Timmer et al., 2016; Kakuta et al., 2018; Gjuladin-Hellon et al., 2019). Table 1 shows the frequency of AEs after thiopurine treatment in IBD (Kakuta et al., 2018; Pugliese et al., 2018; Özgenç et al. 2018; Calafat et al., 2019). Moreover, the appearance of AEs is substantially related to racial differences (Kakuta et al., 2018). AEs are generally categorized into two types: dose-dependent AEs that occur from the pharmacological actions of AZA/6-MP, and dose-independent AEs that are responses to the drug itself. Decreased blood cells, mild alopecia, increased infection susceptibility, and hepatic dysfunction are considered to be dose-dependent AEs, whereas fever, drug eruptions, joint pain, gastrointestinal symptoms, malaise, and acute pancreatitis are considered dose-independent AEs. However, the classification of many AEs is unclear. Gastrointestinal AEs such as nausea, vomiting, and decreased appetite are commonly caused by the compositional binding of the imidazole ring of AZA, and a switch to 6-MP can be beneficial (Kennedy et al., 2013; Calafat et al., 2020). Although conditions can alleviate with time, or proton pump inhibitors and gastrointestinal motility-improving drugs can be clinically effective, thiopurines must be discontinued if symptoms do not improve even after such treatment.

| Ref. | Disease | Case | Leukopenia | Alopecia | Hepatic toxicity | Pancreatic toxicity | Digestive intolerance | Infection | Malignancy |
|------|---------|------|------------|----------|------------------|---------------------|----------------------|-----------|------------|
| Kakuta et al. (2018) | IBD | 1,282 | 18.2% (n = 233) | 6.8% (n = 87) | 3.7% (n = 47) | 1.7% (n = 20) | 13.3% (n = 1) | 6.3% (n = 3) |
| Calafat et al. (2019) | IBD | 17,365 | 6.5% (n = 1,134) | 2.2% (n = 1) | 13.3% (n = 6) | 6.7% (n = 3) | 29.8% (n = 13) | 37.8% (n = 17) |
| Özgenç et al. (2018) | UC | 45 | 28.9% (n = 13) | 6.7% (n = 3) | 6.3% (n = 3) | 28.9% (n = 13) | 37.8% (n = 17) | 4.4% (n = 2) |
| Pugliese et al. (2018) | UC | 48 | 2.1% (n = 1) | 13.3% (n = 6) | 6.7% (n = 3) | 29.8% (n = 13) | 37.8% (n = 17) | 4.4% (n = 2) |

IBD, inflammatory bowel disease; Ref., reference; UC, ulcerative colitis.
with IBD who receive thiopurines, it is important to examine them for EBV infection, regardless of whether the results are positive or negative.

Long-term use of thiopurines represents a substantial risk factor for the onset of LPD, but this risk is thought to decrease when thiopurines are discontinued, depending on the primary disease condition. However, UC relapse is obviously a concern with such discontinuation or withdrawal. According to Moreno-Rincón et al., in a retrospective cohort study examining a median sustained remission period of 33 months in patients with UC not on steroid treatment, relapse was observed after thiopurine withdrawal in 32.4% of patients, and the cumulative relapse rate was 18.9% at 12 months, 36.5% at 36 months, and 43.0% at 60 months (Moreno-Rincón et al., 2015). Similarly, Cassinotti et al. conducted a long-term survey in 155 patients with UC who discontinued AZA during the remission period and found relapse in one-third of patients after 1 year and in half of the patients after 2 years (Cassinotti et al., 2009). We have also previously demonstrated that the relapse rate is greater in the withdrawal group when comparing remission maintenance rates between thiopurine continuation and withdrawal groups of patients with UC with long-term sustained remission, and showed that endoscopic remission (Mayo endoscopic subscore 0) did not guarantee the absence of relapse after withdrawal (Takenaka et al., 2019). As described, a high relapse risk clearly exists with the withdrawal of thiopurines administered as remission maintenance therapy. No clear conclusion has yet been reached on the appropriate and optimal timing of withdrawal, especially considering the concerns for various complications including LPDs after long-term treatment. Nonetheless, due to the various AEs described above, it is necessary to consider thiopurine withdrawal in accordance with disease conditions. Furthermore, thiopurine withdrawal needs to be justified based on assessment of remission with new imaging-enhanced endoscopy or molecular biological examination of tissue samples. Kjærgaard et al. used mucosal biopsy specimens from patients with quiescent UC to analyze mucosal healing in quiescent UC at the molecular and functional level, and reported upregulations of tight junction proteins claudin-2 and claudin-4 mRNA levels, and downregulation of cyclooxygenase-1 enzyme mRNA levels (Kjærgaard et al., 2020). The use of tissue samples to explore mucosal molecular signatures may aid the assessment of remission and could potentially help in deciding when to temporarily withhold thiopurine treatment.

### Use of Thiopurines in IBD Patients During the Coronavirus Disease 2019 (COVID-19) Pandemic

A case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was first reported in December 2019 (Zhu et al., 2020). SARS-CoV-2 is the causative agent of the global COVID-19 pandemic in 2020. Older adults; people with underlying diseases, including diabetes and cardiovascular disease; and patients with cancer are at a high risk of COVID-19. These patients are likely to develop severe symptoms and have a high mortality rate (Liang et al., 2020; Xie et al., 2020; Tian et al., 2021). Therefore, there is an increasing concern among health care professionals regarding the effect of immunosuppressive therapy on patients with IBD who receive corticosteroids, thiopurines, or biological agents. However, there is no evidence to indicate that the suffering from IBD increases the risk of contracting COVID-19. Practice guidelines from organizations such as the International Organization of IBD, the European Crohn’s and Colitis Organization, the British Society of Gastroenterology, and the American Gastroenterological Association recommend that treatment be continued for IBD patients in remission, even during the COVID-19 pandemic, so that remission can be maintained (Dotan et al., 2020; Kennedy et al., 2020; Rubin et al., 2020). These guidelines state that the discontinuation of immunosuppressive therapy for such patients for the purpose of preventing SARS-CoV-2 infections may lead to the use of higher doses of corticosteroids in the case of relapse of IBD, which may expose the patients to a higher risk than that otherwise (Dotan et al., 2020; Kennedy et al., 2020; Rubin et al., 2020). In particular, there is a dearth of evidence regarding the risk of worsening of respiratory infection in patients receiving thiopurines. However, administration of thiopurine drugs is associated with an increased risk of opportunistic viral infections (Seksik et al., 2009; Harbord et al., 2017; Kirchgesner et al., 2018). Mercaptopurine has been shown to inhibit a protease that is essential for the maturation of Middle Eastern Respiratory Syndrome Coronavirus. However, there are no animal-based models that suggest the clinical efficacy of

### Table 2 | Occurrence of lymphoproliferative disorders attributable to thiopurines in patients with IBD.

| Ref [Ref. No] | Case | TP use | Previous TP use | TP never use | TP use (%) | Disease |
|---------------|------|--------|----------------|--------------|------------|---------|
| Beaugerie et al. (2009) | 23/19,486 | 6/5,867 | 2/2,809 | 15/10,810 | UC, CD, and unclassified IBD |
| Ashworth et al. (2012) | 2/1,374 | 2/839 | | 0/535 | UC, CD, and unclassified IBD |
| Pasternak et al. (2013) | 95/43,969 | 9/5,197 | | | UC and CD |
| Khan et al. (2013) | 142/45,683 | 18/4,734 | 5/4,662 | 119/36,297 | UC |
| Beigel et al. (2014) | 4/666 | 3/262 | 1/374 | 0/30 | UC and CD |
| Fukata et al. (2014) | 12/10,500 | 2/1,341 | | 10/9,159 | UC |
| Wang et al. (2016) | 10/2,663 | | | 8.7 | UC |

IBD, inflammatory bowel disease; Ref, reference; TP, thiopurines; UC, ulcerative colitis; CD, Crohn’s disease.
mercaptapurine (Cheng et al., 2015). Based on this finding, many studies have suggested that it is not necessary to discontinue thiopurines in stable patients (Dotan et al., 2020; Kennedy et al., 2020; Rubin et al., 2020).

Currently, there is no evidence based on the ethnicity, age, gender, or treatment to indicate the risks of exacerbation and mortality rates in patients with IBD who have contracted COVID-19. The Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international database for monitoring and reporting the outcomes of COVID-19 in patients with IBD. With the aim of addressing the aforementioned issues, data on cases of IBD patients with COVID-19 are being accumulated in SECURE-IBD for use in various epidemiological studies and therapeutic investigations. Preliminary analyses based on the data obtained from SECURE-IBD have led to recommendations that the administration of immunosuppressants be refrained if a patient with IBD who is receiving immunosuppressant therapy, including thiopurines, contracts COVID-19. The treatment should be ceased until the patient recovers from the infection, owing to the high risk of worsened infections (Allez et al., 2020; Brenner et al., 2020). However, as the background of the patients was not examined in detail in these studies, further investigations are necessary in this regard.

CONCLUSION

In this review, we described the effectiveness, side effects, and challenges of thiopurines in IBD. This review also discussed the use of thiopurine drugs during the COVID-19 pandemic. Thiopurines have been used for many years; however, with the emergence of anti-cytokine therapy in the IBD field, the importance of thiopurines has been revisited. However, there are no practical guidelines for clinicians regarding the use of thiopurines. An increasing number of analyses on TPMT and NUDT15 have elucidated the pharmacological diversity of drugs for which the metabolism is altered by the genetic makeup of an individual. The use of thiopurines as a key anchor drug for the treatment of IBD is expected to continue. Therefore, future research is necessary for providing evidence regarding the benefit–risk balance in cases where thiopurines are used in combination with a new drug and where the use of thiopurines is withdrawn from patients who have been receiving the drugs for a long period. The formulation of practical guidelines at a global level, by considering the ethnic and genetic background, is necessary for improved personalized medicine. It is also essential to establish evidence regarding the risk of infection, risk of exacerbation, suitability of treatment continuation, and drug interactions with concomitant medications, which would serve as a reference during disease pandemics, including COVID-19.

AUTHOR CONTRIBUTIONS

Conceptualization: KT. Writing the original draft preparation: KT. Writing review and editing: KT, TS, TT, and MK Supervision: MI and AI.

ACKNOWLEDGMENTS

We thank Ishida M, lizuka S, and Nakagawa H (Department of Gastroenterology, Dokkyo Medical University) for technical assistance.

REFERENCES

Allez, M., Fleshner, P., Gearry, R., Lakatos, P. L., and Rubin, D. T. (2020). Care of the patient with IBD requiring hospitalization during the COVID-19 pandemic. J. Crohns Colitis 21, S774–S779. doi:10.1093/cecc-jcc/jia150
Ardizzzone, S., Maconi, G., Russo, A., Imbesi, V., Colombo, E., and Bianchi Porro, G. (2006). Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 55, 47–53. doi:10.1136/gut.2005.068809
Asada, A., Nishida, A., Shiroya, M., Imaeda, H., Inatomi, O., Bamba, S., et al. (2016). NUDT15 R139C-related thiopurine leukopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 51, 22–29. doi:10.1007/s00535-015-1142-4
Ashworth, L. A., Billett, A., Mitchell, P., Nuti, F., Siegel, C., and Bousvaros, A. (2012). Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm. Bowel Dis. 18, 838–843. doi:10.1002.ibd.21844
Bartelds, G. M., Krieckaert, C. L., Nurmohamed, M. T., van Schouwenburg, P. A., Lems, W. F., Twisk, J. W., et al. (2011). Development of antidiabetic antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J. Am. Med. Assoc. 305, 1460–1468. doi:10.1001/jama.2011.406
Beaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémani, M., Cosnes, J., et al. (2009). Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617–1625. doi:10.1016/S0140-6736(09)61302-7
Beaugerie, L., Rahier, J. F., and Kirchgesner, J. (2020). Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 18, 1324–1335. doi:10.1016/j.cgh.2020.02.009
Beigel, F., Steinborn, A., Schnitzler, F., Tillack, C., Breiteneicher, S., John, J. M., et al. (2014). Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol. Drug Saf. 23, 735–744. doi:10.1002/pds.3621
Brenner, E. J., Ungaro, R. C., Gearry, R. B., Kaplan, G. G., Kissou-Hunt, M., Lewis, J. D., et al. (2020). Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159, 481–491 e3. doi:10.1053/j.gastro.2020.05.032
Brooke, B. N., Hoffmann, D. C., and Swarbrick, E. T. (1969). Azathioprine for Crohn’s disease. Lancet 294, 612–614. doi:10.1016/s0140-6736(69)90325-0
Calafat, M., Mañosa, M., Cañete, F., Ricart, E., Iglesias, E., Calvo, M., et al. (2019). Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment. Pharmacol. Ther. 50, 780–788. doi:10.1111/apt.15458
Calafat, M., Mañosa, M., Mesonero, F., Guardiola, J., Minguèz, M., Nos, P., et al. (2020). Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA registry. J. Crohns Colitis. 14, 1290–1298. doi:10.1093/cecc-jcc/jiaa055
Candy, S., Wright, J., Gerber, M., Adams, G., Gerg, M., and Goodman, R. (1995). A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 37, 674–678. doi:10.1136/gut.37.5.674
Kotlyar, D. S., Lewis, J. D., Beaugerie, L., Tierney, A., Brensinger, C. M., Gisbert, J. P., et al. (2015). Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. *Clin. Gastroenterol. Hepatol.*, 13, 847–858. doi:10.1016/j.cgh.2014.05.015

Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Lándi, J. K., et al. (2019). British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*, 68, s1-s106. doi:10.1136/gutjnl-2019-318484

Lee, Y. J., Hwang, E. H., Park, J. H., Shin, J. H., Kang, B., and Kim, S. Y. (2016). NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn’s disease. *Eur. J. Gastroenterol. Hepatol.*, 28, 475–478. doi:10.1097/MEG.0000000000000564

Li, D. C., Yang, C. P., Liu, H. C., Jaing, T. H., Chen, S. H., Hung, I. J., et al. (2016). NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. *Pharmacogenomics J.*, 16, 536–539. doi:10.1038/p472015.75

Li, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., et al. (2020). Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.*, 21, 335–337. doi:10.1016/S1470-2045(20)30096-6

Lichtenstein, G. R., Diamond, R. H., Wagner, C. L., Fasanmade, A. A., Olson, A. D., Marano, C. W., et al. (2009). Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. *Aliment. Pharmacol. Ther.*, 30, 210–226. doi:10.1111/j.1365-2636.2009.04007.x

Lowry, P. W., Franklin, C. L., Weaver, A. L., Pike, M. G., Mays, D. C., Tremaine, W. J., et al. (2001). Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. *Gut*, 49, 665–670. doi:10.1136/gut.49.5.665

Macaluso, F. S., Sapienza, C., Ventimiglia, M., Renna, S., Rizzuto, G., Orlando, R., et al. (2018). The addition of an immunosuppressant after loss of response to anti-TNFα monotherapy in inflammatory bowel disease: a 2-year study. *Inflamm. Bowel Dis.*, 23, 189–401. doi:10.1093/ibd/izu010

Marinković, G., Kroon, J., Hoogenboezem, M., Hoek, A. B., Ruiter, M. S., Kurakula, K., et al. (2014). Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. *J. Immunol.*, 192, 4370–4378. doi:10.4049/jimmunol.1302527

Matsumoto, T., Motoya, S., Watanabe, K., Hisamatsu, T., Nakase, H., Yoshimura, N., et al. (2016). Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. *J Crohns Colitis.*, 10, 1259–1266. doi:10.1093/ccc/jyw152

Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., et al. (2018). Evidence-based clinical practice guidelines for inflammatory bowel disease. *J. Gastroenterol.*, 53, 305–353. doi:10.1007/s00535-018-1439-1

Moreno-Rincón, E., Benitez, J. M., Serrano-Ruiz, F. J., Vázquez-Morón, J. M., G. P., et al. (2015). Risk of lymphoma in patients with inflammatory bowel disease during the COVID-19 pandemic: expert commentary. *Gastroenterology*, 159, 350–357. doi:10.1053/j.gastro.2020.04.012

Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., et al. (2017). Tolcetabinib as induction and maintenance therapy for ulcerative colitis. *N. Engl. J. Med.*, 376, 1723–1736. doi:10.1056/NEJMoa1606910

Seksik, P., Cosnes, J., Sokol, H., Nion-Larmurier, I., Gentre, J. P., and Beaugerie, L. (2009). Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Aliment. Pharmacol. Ther.*, 29, 1106–1113. doi:10.1111/j.1365-2036.2009.03973.x

Shah, S. A., Paradkar, M., Desai, D., and Ashaved, T. F. (2017). Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. *J. Gastroenterol. Hepatol.*, 32, 620–624. doi:10.1111/jgh.13494

Smith, R. M., and Cooper, S. C. (2014). Mycophenolate mofetil therapy in the management of inflammatory bowel disease—a retrospective case series and review. *J Crohns Colitis.*, 8, 890–897. doi:10.1016/j.jcjo.2014.01.014

Soler, A. M., Oläno, N., Ménendez, Y., Lopes, A., Silvera, A., Dabezies, A., et al. (2018). TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay. *Br. J. Haematol.*, 181, 252–255. doi:10.1111/bjh.14532

Sparrów, M. P., Hande, S. A., Friedman, S., Cao, D., and Hanauer, S. B. (2007). Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. *Clin. Gastroenterol. Hepatol.*, 5, 209–214. doi:10.1016/j.cgh.2006.11.020

Sparrów, M. P., Hande, S. A., Friedman, S., Lim, W. C., Reddy, S. I., Cao, D., et al. (2005). Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. *Aliment. Pharmacol. Ther.*, 22, 441–446. doi:10.1111/j.1365-2036.2005.02583.x

Takahashi, F., Tominaga, K., Takanomi, K., Koshino, A., Sugaya, T., et al. (2016). Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. *Scand. J. Gastroenterol.*, 51, 827–834. doi:10.1080/0300365521.2016.1141315

Takanomi, K., Tominaga, K., Kanazawa, M., Fukushima, K., Tanaka, T., Kanamori, A., et al. (2019). Endoscopic score vs blood cell indices for determining timing of...
immunomodulator withdrawal in quiescent ulcerative colitis. Sci. Rep. 9, 17751. doi:10.1038/s41598-019-45469-7

Tanaka, Y., Kato, M., Hasegawa, D., Urayama, K. Y., Nakadate, H., Kondoh, K., et al. (2015). Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br. J. Haematol. 171, 109–115. doi:10.1111/bjh.13518

Tian, Y., Qiu, X., Wang, C., Zhao, J., Jiang, X., Niu, W., et al. (2021). Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int. J. Cancer 15, 363–374. doi:10.1002/ijc.33213

Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., et al. (2003). CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111, 1133–1145. doi:10.1172/JCI16432

Timmer, A., Patton, P. H., Chande, N., McDonald, J. W., and MacDonald, J. K. (2016). Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 18, CD000478. doi:10.1002/14651858.CD000478

van Schouwenburg, P. A., Krieckaert, C. L., Rispens, T., Aarden, L., Wolbink, G. J., and Wouters, D. (2013). Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann. Rheum. Dis. 72, 1680–1686. doi:10.1136/annrheumdis-2012-202407

Walker, G. J., Harrison, J. W., Heap, G. A., Voskuil, M. D., Andersen, V., Anderson, C. A., et al. (2019). Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. J. Am. Med. Assoc. 321, 773–785. doi:10.1001/jama.2019.0709

Wang, L. H., Yang, Y. J., Cheng, W. C., Wang, W. M., Lin, S. H., and Shieh, C. C. (2016). Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan. Am. J. Gastroenterol. 111, 1313–1319. doi:10.1038/ajg.2016.239

Wang, L., and Weinshilboum, R. (2006). Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene. 25, 1629–1638. doi:10.1038/sj.onc.1209372

Wang, Y., MacDonald, J. K., Vandermeer, B., Griffiths, A. M., and El-Matary, W. (2015). Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 11, CD007560. doi:10.1002/14651858.CD007560

Xie, Y., Wang, Z., Liao, H., Marley, G., Wu, D., and Tang, W. (2020). Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect. Dis. 20, 640. doi:10.1186/s12879-020-05371-2

Xiong, Y. J., Deng, Z. B., Liu, J. N., Qiu, J. J., Guo, L., Feng, P. P., et al. (2019). Enhancement of epithelial cell autophagy induced by sinensetin alleviates epithelial barrier dysfunction in colitis. Pharmacol. Res. 148, 104461. doi:10.1016/j.phrs.2019.104461

Yang, S. K., Hong, M., Baek, J., Choi, H., Zhao, W., Jung, Y., et al. (2014). A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46, 1017–1020. doi:10.1038/ng.3060

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. doi:10.1056/NEJMoa2001017

Zhu, X., Wang, X. D., Chao, K., Zhi, M., Zheng, H., Ruan, H. L., et al. (2016). NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn’s disease. Aliment. Pharmacol. Ther. 44, 967–975. doi:10.1111/apt.13796

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Tominaga, Sugaya, Tanaka, Kanazawa, Iijima and Irisawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.